ArticleClinical kidney journal2019
Is polypharmacy an increasing burden in chronic kidney disease? The German experience.
Article in Clinical kidney journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Prevalence and global trends of polypharmacy in patients with chronic kidney disease: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Hyperpolypharmacy in patients with chronic kidney disease and its impact on clinical outcomes.Scientific reports · 2026Article
- Association between polypharmacy and chronic kidney disease among community-dwelling older people: a longitudinal study in southern China.BMC nephrology · 2024Article
- Drug utilisation study in hospitalised chronic kidney disease patients, using World Health Organisation prescribing indicators: an observational study.Journal of pharmaceutical policy and practice · 2024Article
- Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Polypharmacy, chronic kidney disease, and mortality among older adults: A prospective study of National Health and nutrition examination survey, 1999-2018.Frontiers in public health · 2023Article
- Polypharmacy, chronic kidney disease, and incident fragility fracture: a prospective cohort study.Journal of bone and mineral metabolism · 2022Article
- Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls.Clinical kidney journal · 2021Article
- Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Drug-drug interactions in polypharmacy patients: The impact of renal impairment.Current research in pharmacology and drug discovery · 2021Review
- Differential Diagnoses and Clinical Implications of Medication Nonadherence in Older Patients with Chronic Kidney Disease: A Review.Drugs & aging · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a commentary article describing the key findings of the German chronic kidney disease (GCKD) study and how these relate to current practice. With the GCKD study showing high levels of polypharmacy, this article discusses ways to ensure that polypharmacy is appropriate and the difficulties faced within a chronic kidney disease population. Suggestions of ways to minimize medication burden in renal patients provide some practical advice for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.